Pioneer Trust Bank N A OR lowered its position in shares of C R Bard Inc (NYSE:BCR) by 1.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 9,627 shares of the medical instruments supplier’s stock after selling 165 shares during the quarter. Pioneer Trust Bank N A OR’s holdings in C R Bard were worth $3,192,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Monroe Bank & Trust MI lifted its position in C R Bard by 65.6% during the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 177 shares during the period. Valeo Financial Advisors LLC purchased a new position in C R Bard during the third quarter valued at $170,000. Patten Group Inc. lifted its position in C R Bard by 66.0% during the third quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 221 shares during the period. Glovista Investments LLC purchased a new position in C R Bard during the second quarter valued at $221,000. Finally, Fieldpoint Private Securities LLC purchased a new position in C R Bard during the third quarter valued at $234,000. 79.11% of the stock is owned by institutional investors and hedge funds.

In other news, VP John A. Deford sold 14,107 shares of C R Bard stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $333.48, for a total transaction of $4,704,402.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Vice Chairman John H. Weiland sold 33,435 shares of C R Bard stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $333.31, for a total value of $11,144,219.85. Following the transaction, the insider now directly owns 76,331 shares in the company, valued at $25,441,885.61. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 114,602 shares of company stock valued at $38,193,867. Corporate insiders own 0.80% of the company’s stock.

Shares of C R Bard Inc (NYSE BCR) opened at $331.24 on Friday. C R Bard Inc has a twelve month low of $222.42 and a twelve month high of $337.73. The company has a market capitalization of $24,140.00, a PE ratio of 43.64, a P/E/G ratio of 2.53 and a beta of 0.52. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.72 and a quick ratio of 1.37.

C R Bard (NYSE:BCR) last released its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.96 by $0.06. The business had revenue of $989.80 million during the quarter, compared to the consensus estimate of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. During the same period in the previous year, the company posted $2.64 EPS. analysts predict that C R Bard Inc will post 11.89 earnings per share for the current fiscal year.

Several brokerages have commented on BCR. Barclays raised their price objective on C R Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th. ValuEngine lowered C R Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Needham & Company LLC restated a “hold” rating on shares of C R Bard in a report on Thursday, October 26th. Cowen restated a “hold” rating and set a $317.00 price target on shares of C R Bard in a report on Friday, November 3rd. Finally, Zacks Investment Research upgraded C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target for the company in a report on Tuesday, December 26th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. C R Bard currently has a consensus rating of “Hold” and an average price target of $311.43.

COPYRIGHT VIOLATION NOTICE: “Pioneer Trust Bank N A OR Sells 165 Shares of C R Bard Inc (BCR)” was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://theolympiareport.com/2018/01/19/pioneer-trust-bank-n-a-or-sells-165-shares-of-c-r-bard-inc-bcr.html.

C R Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Institutional Ownership by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.